STOCK TITAN

Fate Therapeutic - FATE STOCK NEWS

Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.

Fate Therapeutics, Inc. (NASDAQ: FATE) is a transformative approach to cellular immunotherapy through its proprietary induced pluripotent stem cell (iPSC) platform. This page serves as the definitive source for verified news and press releases directly from the clinical-stage biopharmaceutical leader.

Access real-time updates on clinical trial progress, regulatory milestones, and strategic partnerships driving next-generation cancer treatments and autoimmune therapies. Investors will find essential announcements including quarterly earnings, product pipeline advancements, and manufacturing developments related to off-the-shelf CAR T-cell and NK-cell programs.

Our curated collection includes filings with the SEC, peer-reviewed research publications, and updates on multiplexed-engineered iPSC lines. Stay informed about the company’s pioneering work in creating pharmaceutical-grade cell products that aim to overcome limitations of traditional donor-derived therapies.

Bookmark this page for streamlined tracking of Fate Therapeutics’ progress in immuno-oncology and regenerative medicine. Check regularly for authoritative updates on clinical data readouts, collaboration expansions, and technological breakthroughs in stem cell biology.

Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) reported Q2 2024 financial results and business updates. Key highlights include:

1. Ongoing enrollment in FT819 Phase 1 autoimmunity study for SLE, now including single-agent cyclophosphamide as an alternative conditioning regimen.

2. First patient treated with FT522 CAR NK cell product in conditioning-free arm of Phase 1 B-cell lymphoma study.

3. FT522 multi-indication IND for autoimmune diseases to be submitted in Q3 2024.

4. Enrollment ongoing for FT825/ONO-8250 CAR T-cell product in Phase 1 solid tumor study.

5. $352 million in cash and investments, with projected runway through 2026.

6. Q2 2024 revenue of $6.8 million, including a $5 million milestone from Ono Pharmaceutical.

7. GAAP operating expenses of $51.9 million for Q2 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
-
Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced new employee inducement awards. On August 1, 2024, the company granted restricted stock units (RSUs) representing 34,200 shares of common stock to four newly-hired non-executive employees. These grants were approved by the Compensation Committee and issued under the company's Amended and Restated Inducement Equity Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continuous employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.5%
Tags
management
-
Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) has appointed Dr. Neely Mozaffarian to its Board of Directors. Dr. Mozaffarian brings over 20 years of experience in immunology and autoimmunity research and drug development. This appointment comes as Fate Therapeutics expands its clinical investigation of iPSC-derived cell products for autoimmune diseases.

The company recently treated its first systemic lupus erythematosus patient with FT819, an off-the-shelf, iPSC-derived CD8αβ+ T-cell product candidate. The patient, a 27-year-old woman with refractory disease, received a single dose of 360 million cells and was discharged after three days without notable adverse events.

Dr. Mozaffarian's expertise is expected to benefit Fate Therapeutics as it advances its pipeline of cell therapies for autoimmune conditions. Her background includes leadership roles at Atomwise, GentiBio, Janssen Pharmaceuticals, and other major pharmaceutical companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
management
Rhea-AI Summary

Fate Therapeutics, a clinical-stage biopharmaceutical company focused on induced pluripotent stem cell (iPSC)-derived cellular immunotherapies, announced employee inducement awards under Nasdaq Listing Rule 5635(c)(4). On July 1, 2024, the company granted restricted stock units (RSUs) totaling 28,200 shares of common stock to three newly-hired non-executive employees. These grants were approved by the Compensation Committee and will vest over four years, with 25% vesting annually, contingent on the employees' continuous employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
management
-
Rhea-AI Summary

Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune disorders, announced new employee inducement awards under Nasdaq Listing Rule 5635(c)(4). On June 1, 2024, the company granted a non-qualified stock option to one new employee to purchase a total of 65,000 shares at an exercise price of $3.68 per share, the closing price on May 31, 2024. Additionally, Fate Therapeutics granted restricted stock units (RSUs) representing 14,500 shares to three new non-executive employees. These grants were approved by the Compensation Committee and are part of the company's Amended and Restated Inducement Equity Plan. Both the stock options and RSUs will vest over four years, contingent on continuous employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
management
-
Rhea-AI Summary

Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an archived version available post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
conferences
Rhea-AI Summary

Fate Therapeutics reported its first quarter 2024 financial results and business updates, highlighting progress in clinical areas, including treating the first lupus patient with FT819 CAR T-cell therapy, initiating enrollment for FT522 CAR NK cell therapy, and treating the first patient with FT825 CAR T-cell therapy. The company has $391 million in cash, cash equivalents, and investments. The financial results include $1.9 million in revenue, $53.0 million in operating expenses, and total outstanding shares of 113.8 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
-
Rhea-AI Summary

Fate Therapeutics announced the treatment of the first lupus patient in the Phase 1 autoimmunity study of FT819 CAR T-cell program. The patient showed rapid and potent depletion of CD19+ B cells. The company also presented translational data from the Phase 1 study of FT819 in B-cell malignancies and initial clinical observations from the FT522 CAR NK cell program in B-cell lymphoma. These programs highlight key therapeutic mechanisms for autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
-
Rhea-AI Summary

Fate Therapeutics, Inc. will report its first quarter 2024 financial results and operational updates during a conference call on May 9, 2024. The company focuses on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, with programs like FT819 and FT522. The event coincides with the American Society of Gene and Cell Therapy 27th Annual Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
conferences earnings
Rhea-AI Summary

Fate Therapeutics announced preclinical data for its FT522 program for autoimmune diseases at the ASGCT Annual Meeting. FT522, a CD19-targeted CAR NK cell product candidate, showed promising results in depleting SLE donor B cells and eliminating host immune cells. The ADR technology incorporated into FT522 enhances its potency, potentially offering a new treatment approach for autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
Fate Therapeutic

Nasdaq:FATE

FATE Rankings

FATE Stock Data

127.21M
110.37M
2.27%
89.8%
11.63%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO